Successful Treatment of PulmonaryInvasive Aspergillosis with Voriconazole in Patients who FailedConventional Therapy by Garbino, J. et al.
Infection 31 · 2003 · No. 4 © URBAN & VOGEL 241
Successful Treatment of Pulmonary Invasive
Aspergillosis with Voriconazole in Patients who
Failed Conventional Therapy
J. Garbino, P. Rohner, L. Kolarova, A. Ondrusova, D. Lew
Abstract
Background: The incidence of fungal infections, including
those due to Aspergillosis species has continued to increase
in recent years. Invasive aspergillosis remains an important
cause of morbidity and mortality, despite therapeutics
interventions.
Patients and Methods: We reported five cases of invasive
pulmonary aspergillosis treated with voriconazole failing to
respond to conventional treatments.
Results: The clinical and radiological resolution of
pulmonary aspergillosis reported in these cases following
therapy with voriconazole is remarkable, considering the
infections had proved refractory to standard antifungal
therapies. Long-term therapy (in two cases ≥ 1 year, in one
case 6 months) was very well tolerated by patients who were
unable to tolerate other antifungal agents.
Conclusion: Therapy with voriconazole offers a new
therapeutic option for otherwise difficult-to-treat infections
and the potential to significantly improve the management
of Aspergillosis infections.
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Introduction
The incidence of fungal infections, including those due to
Aspergillus species, has continued to increase in recent
years. Invasive aspergillosis remains an important cause of
morbidity and mortality, despite therapeutic interventions
[1]. Survival of patients with invasive pulmonary as-
pergillosis is generally very poor, at least partly due to the
lack of effective treatment options for this disease [2]. As-
pergillus spp. are widespread in the environment and are
the most common cause of invasive mould infections in
immunocompromised individuals [3]. Aspergillus infections
can result in pneumonia and brain abscesses in this popu-
lation, which includes patients with burns, HIV infection,
cancer, organ transplant recipients and those receiving im-
munosuppressive therapy [4–6]. Although the overall inci-
dence of invasive aspergillosis is not high, certain patient
populations are at particular risk. The disease typically af-
fects 5% of bone marrow transplant recipients, 15% of pa-
tients with hematological malignancies and 10–14% of solid
organ transplantation cases [7, 8].
Early initiation of antifungal therapy is associated with
improved clinical outcomes [9]. However, as conventional
treatments can result in severe adverse reactions and com-
plications, rapid diagnosis of the infection is also vital. The
incidence of Aspergillus colonization is very high in respi-
ratory samples, so early diagnosis of invasive pulmonary as-
pergillosis remains difficult. By the time the infection is con-
firmed, mortality may reach 50–95% in patients with dis-
seminated infection [5].
Voriconazole is a new broad-spectrum triazole anti-
fungal agent with activity against a wide range of clinically
important and emerging fungal pathogens. Studies have
shown voriconazole to result in good clinical responses in
60% of patients with acute pulmonary or tracheobronchial
invasive aspergillosis [10] and to be both more effective and
better tolerated than amphotericin B in patients with inva-
sive aspergillosis [11].When used empirically in febrile neu-
tropenic patients, voriconazole is a suitable alternative to
liposomal amphotericin B, with fewer breakthrough infec-
tions (including those due to Aspergillus spp.) occurring




A 74-year-old Caucasian male with right nephrectomy due to gen-
itourinary tuberculosis and ischemic cardiopathy since 1998, suf-
fered terminal renal failure due to nephroangiosclerosis. He had
received hemodialysis since 1996 and underwent renal transplan-
tation in February 2000. Immunosuppressive therapy consisted of
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prednisone (25 mg od), mycophenolate mofetil (1,000 mg bid) and
tacrolimus (2 mg bid).
Two months after transplantation, the patient was hospital-
ized due to febrile agranulocytosis in the context of immunosup-
pressive therapy and pulmonary aspergillosis was suspected on the
basis of chest X-rays (cavitary image). Although Aspergillus was
not detected in tracheal secretions, the patient was treated with
itraconazole (200 mg bid), due to the high risk of aspergillosis and
was discharged from the hospital.
One month later, thoracic CT scans revealed a rosette-type
excavated infiltrate on the left side and bilateral parenchymatous
infiltrates (Figure 1). Laboratory follow-ups showed an increase
in neutrophil count after a further 2 weeks and the patient re-
ported severe asthenia. He was rehospitalized and Aspergillus fu-
migatus was cultured from bronchoalveolar lavage (BAL); renal
insufficiency was still present. Due to the severity of disease, im-
munosuppressive therapy was reduced and iv voriconazole treat-
ment (6 mg/kg q12h iv  2 doses on day 1, followed by 200 mg bid
orally) was initiated. Treatment with amphotericin B was not in-
troduced due to renal impairment. The patient was treated with
voriconazole for 1 year, resulting in a clear improvement in tho-
racic CT scans (compared to the 1st month) and the pulmonary
lesions were considered cured.
Adverse events observed during voriconazole treatment were
dizziness and ocular disturbances, which both occurred during the
initial infusion, a few minutes later the patient recovered without
sequelae.Voriconazole treatment was well tolerated for 1 year and
no liver function test abnormalities were observed.
Case 2
A 37-year-old Caucasian male with a past medical history of
chronic granulomatous disease since the age of 14 years, inguinal
adenitis caused by Candia albicans, pulmonary anguilliasis  and
type 1 diabetes mellitus presented in January 2000 with tracheo-
bronchitis and received clarithromycin therapy.
One month later, the patient reported recurrence of cough
with purulent sputum, night sweating and weight loss (3–4 kg). A
subcutaneous tumefaction was noted below the left breast and A.
fumigatus was cultured from the biopsy. Thoracic CT scans indi-
cated a large subpectoral mass on the left side, corresponding with
an area of pleural thickness. The scans also revealed osteolytic
changes to the fourth and fifth anterior left ribs, a pulmonary ab-
scess in contact with pericardium, mediastinal adenopathies, infil-
trates and pleuro-parenchymatous synechia in the lingula lobe
(Figure 2). Bone scintigraphy showed hyperactivity in the fourth
and fifth anterior left ribs.
Treatment was started with conventional amphotericin B
(1 mg/kg/day), but was switched to a lipid formulation 11 days later
(Ambisome® 3 mg/kg/day) due to adverse events (anemia and re-
nal insufficiency). This treatment regimen was maintained for 6
weeks, during which time renal insufficiency improved, but a blood
transfusion was necessary to correct the persistent anemia.The pa-
tient was then switched to therapy with voriconazole (6 mg/kg
q12h iv  2 doses on day 1, followed by 200 mg bid orally). One
month later, CT scans indicated that the pectoral mass on the left
side had resolved and that the infiltrates in the superior left lobe
were slightly reduced. A small parenchymatous pulmonary con-
densation at the level of the lingual lobe persisted, as did the
adenopathies. A follow-up CT scan 1 year later showed further
improvement in the pulmonary infiltrates.
The patient tolerated voriconazole treatment very well. Af-
ter 1 year of treatment, a cutaneous rash attributable to the drug
occurred, which improved when voriconazole was reduced from
200 mg bid to 150 mg bid orally. The patient continues to receive
prophylactic treatment with voriconazole.
Case 3
A 65-year-old Caucasian male had a past medical history of viral
pericarditis and idiopathic pulmonary fibrosis, which was treated
with immunosuppressive drugs.
In November 1998, the patient underwent bi-pulmonary
transplantation.Three days later, A. fumigatus and C. albicans were
cultured from the respiratory tract. In the context of immunosup-
pressive therapy and suspected pulmonary aspergillosis with a
compatible chest X-ray, excavated infiltrates, itraconazole therapy
was initiated (400 mg/day). Bronchoscopy 1 week later revealed
sutures covered by plaques on the left side, which reached the right
superior bronchus and biopsy cultured A. fumigatus.Amphotericin
B was stopped due to patient’s intolerance. Due to lack of response
J. Garbino et al. Voriconazole for Treating Invasive Aspergillosis
242 Infection 31 · 2003 · No. 4 © URBAN & VOGEL
Figure 1. Thoracic CT scan showing a pulmonary rosette-type exca-
vated infiltrate on the left side, bilateral parenchymatous infiltrates
and adenopathies.
Figure 2. Thoracic CT scan showing a pulmonary abscess in contact
with the pericardium and chest wall, mediastinal adenopathies, infil-
trates and pleuro-parenchymatous synechia in the lingual lobe.
to itraconazole, voriconazole therapy was started 1 month after
transplantation (6 mg/kg q12h iv  2 doses on day 1, followed by
200 mg bid orally). Respiratory tract cultures became negative and
the infection was considered cured after 3 months of treatment.
The patient died 5 months later, due to a cardiorespiratory arrest.
Case 4
A 56-year-old Caucasian male had a past medical history of a
leukemia diagnosed in 2001 and wastreated with chemotherapy.
During chemotherapy, the patient developed thrombocytopenia
and severe anemia, which necessitated blood transfusions. Neu-
tropenia below 500 granulocytes/l lasted for 2 days.
In September 2001, blepharoconjunctivitis occurred and the
patient was treated with cefepime and teicoplanin for 4 weeks; acy-
clovir was also administered for 3 weeks, due to positive herpes
serology. One month later, the patient became febrile and a fungal
infection was suspected. Amphotericin B therapy (1 mg/kg/day)
was initiated, and pulmonary aspergillosis was subsequently con-
firmed by thoracic CT scans (halo sign) and positive serologic test
(galactomanan). Due to intolerance of the amphotericin B treat-
ment (renal impairment and hypokalemia), the patient was
switched to voriconazole (6 mg/kg q12h iv  2 doses on day 1, fol-
lowed by 200 mg bid orally) for 6 months, which resulted in reso-
lution of the radiological images. The patient did not present any
drug intolerance.
Case 5
A 77-year-old Caucasian male had a past medical history of res-
piratory insufficiency due to pulmonary fibrosis and was treated
with prednisone (20 mg/day) and azathioprine (25 mg/day).
The patient was admitted to hospital with bronchopneumo-
nia and respiratory insufficiency. Antimicrobial treatment
(imipenem, clarithromycin) was initiated, but no clinical response
was observed. Invasive pulmonary aspergillosis was diagnosed by
lung biopsy (cultures grew A. fumigatus), and itraconazole ther-
apy (400 mg/day) was started. After 1 week, no clinical improve-
ment was observed and treatment was switched to amphotericin
B (1 mg/kg/day). The patient developed renal failure and was
switched to voriconazole (6 mg/kg q12h iv  2 doses on day 1, fol-
lowed by 200 mg bid orally).The patient’s clinical condition wors-
ened, he developed septic shock and was transferred to the inten-
sive care unit. He required mechanical ventilation and vasopres-
sors (ephedrine and dobutamine), but died 3 days later; death was
not attributable to fungal infection.
Discussion
The clinical and radiological resolution of pulmonary as-
pergillosis reported in these cases following therapy with
voriconazole is remarkable, considering the infections had
proved refractory to standard antifungal therapies. Long-
term therapy (in two cases ≥ 1 year, in one case 6 months)
was very well tolerated by patients who were unable to tol-
erate other antifungal agents, including those with under-
lying conditions such as renal insufficiency, which can re-
strict the selection of conventional antifungal agents.
Voriconazole appears to offer a new therapeutic option for
otherwise difficult-to-treat infections, such as those in pa-
tients with chronic granulomatous disease. Echinocandins
could be another treatment alternative. Therapy with
voriconazole also offers the potential to significantly im-
prove the management of Aspergillus infections. In the
cases reported here, aspergillosis was considerably im-
proved or resolved and the clinical conditions of these in-
dividuals were stabilized. Using voriconazole to stabilize
patients with previously difficult-to-treat infections may ul-
timately allow long-term therapeutic interventions, such as
bone marrow transplantation, to be undertaken.
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